

January 20, 2025

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Takaaki Fukushima
Vice President Corporate Officer and Chief Financial Officer
TEL: +81-3-5472-1125

Notice Regarding Adjustment of Exercise Price

SymBio Pharmaceuticals Limited (the “Company”) hereby announces that in conjunction with the issue of fifth unsecured convertible bonds with stock acquisition rights allotment to Cantor Fitzgerald Europe, which was resolved at the Board of Directors’ meeting held on Monday, January 20, 2025, it will revise the exercise price of Share Acquisition Rights, as below.

1. Adjustment of Exercise Price

Name of stock acquisition rights	Exercise price after adjustment	Exercise price before adjustment
SymBio Pharmaceuticals Limited’s 58th Stock Acquisition Rights	¥171	¥182.7

2. Applicable Date

From Wednesday, February 5, 2025

3. Reason for Adjustment

The exercise price will be adjusted because the payment amount for the issue of fifth unsecured convertible bonds with stock acquisition rights allotment to Cantor Fitzgerald Europe (resolved at a Board of Directors’ meeting held on Monday, January 20, 2025) resolved on Monday, January 20, 2025, was lower than the exercise price effective as of the applicable commencement date stipulated in 10, Item (2), 2) of the Terms and Conditions for the Issuance of SymBio Pharmaceuticals Limited’s 58th Stock Acquisition rights.